Mr. Daniel S. Lynch is an Independent Director at Omega Alpha SPAC, a Chairman at Xilio Therapeutics, Inc., a Chairman at Springworks Therapeutics, Inc., an Executive Chairman at SpringWorks Therapeutics LLC, an Executive Chairman at Blueprint Medicines Corp., a Chairman at Translate Bio, Inc. and a Chairman at bluebird bio, Inc. He is on the Board of Directors at Omega Alpha SPAC. Mr. Lynch was previously employed as an Executive Chairman by eGenesis, Inc., an Executive Chairman by Surface Oncology, Inc., an Executive Chairman by Proclara Biosciences, Inc., an Independent Director by Sesen Bio, Inc., an Executive Chairman by Nimbus Discovery LLC, a Chairman by BIND Therapeutics, Inc., an Entrepreneur-in-Residence by Third Rock Ventures LLC, an Executive Chairman by Avila Therapeutics, Inc., a Chairman by Stromedix, Inc., a Chief Executive & Financial Officer by ImClone Systems, Inc., a Vice President-Finance by Bristol Myers Squibb Co., a Chief Financial Officer by Derby Cycle Corp., a Chief Executive & Financial Officer by ImClone Systems Corp., a President & Chief Executive Officer by Ivrea Pharmaceuticals, Inc., and a Vice President-Finance by US Pharmaceuticals, Inc. He also served on the board at The Brain Injury Network of Dallas, Edimer Pharmaceuticals, Inc., Ember Therapeutics, Inc. /Old/, US Oncology, Inc. and US Oncology Holdings, Inc. He received his undergraduate degree from Wesleyan University and an MBA from the University of Virginia Darden School of Business.